Arrowhead Pharmaceuticals’ (ARWR) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report sent to investors on Tuesday,Benzinga reports. Piper Sandler currently has a $110.00 price target on the biotechnology company’s stock, up from their prior price target of $100.00.

Several other analysts have also weighed in on ARWR. The Goldman Sachs Group upped their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 7th. HC Wainwright raised their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Chardan Capital lifted their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, Royal Bank Of Canada increased their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $73.00.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $66.25 on Tuesday. The firm has a market capitalization of $9.00 billion, a price-to-earnings ratio of -828.02 and a beta of 1.21. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The business’s 50 day simple moving average is $59.36 and its 200-day simple moving average is $37.88. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $76.76.

Insider Activity at Arrowhead Pharmaceuticals

In other news, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares in the company, valued at $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the transaction, the director directly owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. This represents a 22.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 510,836 shares of company stock worth $33,603,060 over the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 3.1% in the third quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 326 shares during the period. State of Wyoming boosted its stake in Arrowhead Pharmaceuticals by 5.6% in the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock worth $328,000 after buying an additional 504 shares during the last quarter. Arizona State Retirement System grew its holdings in Arrowhead Pharmaceuticals by 1.9% in the 3rd quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock valued at $1,126,000 after buying an additional 620 shares during the period. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 6.7% during the 3rd quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 764 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $29,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.